Letter to the Secretary of Health and Human Services Requesting an Investigation of the FDA’s Inappropriate Close Collaboration with Biogen on the Alzheimer’s Disease Drug Aducanumab

View as PDF
View press release

Public Citizen called on Secretary of Health and Human Services Xavier Becerra to ask his department’s Office of Inspector General to immediately investigate the unprecedented and inappropriate close collaboration between the Food and Drug Administration (FDA) and Biogen regarding the company’s application for approval of the Alzheimer’s disease drug aducanumab. The economic costs of the aducanumab to the Medicare program would be extraordinary and only justifiable for a drug that has definitive evidence of significant, clinically meaningful benefit.

See Public Citizen’s other work on aducanumab.